Imprimis Pharma (IMMY) Misses Q1 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Imprimis Pharmaceuticals Announces First Quarter 2016 Financial Results and Provides Business Update
May 12, 2016 4:05 PM EDTSAN DIEGO, May 12, 2016 /PRNewswire/ --Â Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding business model, today reported financial results for the first quarter 2016, and will provide an update on recent business developments on a conference call this afternoon.Â
In comparing the first quarter revenue figures of 2016 to the same period of 2015, the company reported... More
